Indication
In the female:
1. Ovulation induction in infertility due to anovulation or impaired follicle-ripening.
2. Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (ART).
3. Luteal phase support.
4.Threatened and habitual abortion.
In the male:
1. Hypogonadotropic hypogonadism (also cases of idiopathic dysspermias have shown a positive response to gonadotropins).
2. Used to treat oligospermia.
3. Delayed puberty associated with insu cient gonadotropic pituitary function.
Dosage & Administration
Injection provided, immediately prior to use.
In the female:
Anovulatory infertility: HCG Inj. 5000 IU to 10000 IU is administered in mid-cycle, following
treatment with Menotrophin Inj. according to a recognised scheme. Details of Menotrophin
Inj. dosage and monitoring are available on request.
Luteal phase support: Two repeat injections of 2500 IU to 5000 IU. Each may be given
within nine days following ovulation or embryo transfer (for example on day 3, 6 and 9 after
ovulation induction).
In the male:
Oligospermia: 2500 IU to 5000 IU HCG, two times per week. During this treatment
testosterone replacement therapy should be suspended.
Hypogonadotropic hypogonadism: 2500 IU to 5000 IU HCG, two times per week. If the
main complaint is sterility, additional doses of an FSH-containing (75 IU FSH or 75 IU
HMG) are to be administered daily or two to three times a week. This treatment should be
continued for at least three months before any improvement in spermatogenesis can be
expected. During this treatment testosterone replacement therapy should be suspended.
Once achieved, the improvement may in some cases be maintained by HCG alone.
Precautions
1. In pregnancies occurring after induction of ovulation with gonadotropic preparations, there is an increased risk of multiplets birth.
2. Unwanted ovarian hyperstimulation: In patients treated for infertility due to anovulation or impaired follicular ripening, the prior administration of an FSH containing preparation may lead to unwanted ovarian hyperstimulation. Therefore ultrasonic assessment of follicular development and determinations nations of estrogen levels should be performed prior to FSH-treatment and at regular intervals during FSH-treatment. Estrogen levels may rise very rapidly, e.g. more than a daily doubling for two or three consecutive days, and possibly reach excessively high values. If this unwanted ovarian hyperstimulation occurs (i.e. not as part of a treatment preparing for IVF/ET or GIFT/ZIFT), the administration of the FSH-containing preparation should be discontinued immediately. In that case Human Chorionic Gonadotrophin must not be given, because the administration of an LH-active gonadotrophin at this stage may induce, in addition to multiple ovulations, the ovarian hyperstimulation syndrome. This warning is particularly important with respect to patients with polycystic ovarian disease. Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (pain, nausea, diarrhoea), painful breasts, and mild to moderate enlargement of ovaries and ovarian cysts. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by Pregnancy and Lactation Human chorionic gonadotrophin may be used for luteal phase support in pregnancy.
